Dataset opportunity
Clariamedical — 医疗影像数据集机会
Clariamedical 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
66.4
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场 = 2025 年为 18 亿美元，CAGR 为 35.1%。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-09-08
This de novo minimally invasive system was designed for safer hysterectomies
medicaldesignandoutsourcing.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（PII 审查）
Buyer persona
医疗人工智能与诊断影像公司
Clariamedical 持有一个专门的医疗影像数据集，该数据集源自妇科手术和组织切除术。该数据集整合了高分辨率的图像模态数据以及相应的物联网设备数据、电子medical_records和临床试验的监管文件。这种多方面证据使其非常适合训练和验证旨在改善妇科手术结果和病理检测的诊断人工智能模型。
该数据定位在全球医疗影像人工智能市场内，该市场在 2025 年的估值为 18 亿美元，预计将以 CAGR 35.1% 的速度增长。[1] 尽管存在 HIPAA 和 IRB 批准要求等访问复杂性，但该数据集的稀有性及其在快速增长领域中的直接适用性使其成为寻求竞争优势的人工智能开发者的宝贵资产。⚠ 尽职调查（有价值的数据，可协商访问）：医疗数据受严格的 HIPAA 和临床试验保密法规约束；数据访问可能需要去标识化和机构审查委员会 (IRB) 批准；数据集高度专业化，适用于妇科手术和组织切除术 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据表明 Clariamedical 拥有一份在 Claria System (K192455) 获批过程中生成的专有、FDA 验证的医疗影像数据集。这一独特的临床性能、设备级和监管数据集合是诊断人工智能开发者的主要资产，他们寻求使用高质量的ground-truth数据来训练和验证算法。在全球医疗影像人工智能市场预计到 2025 年将达到 18 亿美元的情况下，该数据集提供了一个难得的机会，可以针对监管级基准构建模型，从而加速任何医疗人工智能公司的市场进入。
See dimension details ↓- Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
需求由医疗影像人工智能市场的快速增长驱动，该市场正以 35.1% 的 CAGR 扩张，从而产生了对高质量、专业化培训数据的强烈需求。[1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Dataset Specificity90
占主导地位的“medical_records”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=gdpr_敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 个数据需求信号（0 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
盈余=中等，1 个近期外部信号 — 超出已货币化数据的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ 良好目标 — 这是一个良好目标；它是一家运营中的医疗设备公司，最近获得了 FDA 授权并正在准备商业发布，这意味着它将作为其核心业务的副产品生成有价值的临床和运营数据。问题：初始提示描述“医疗影像数据集机会”具有误导性。公司的核心业务不是销售数据，而是开发和销售；有一家不同的公司 ClariMed，似乎是一家数据/隐私咨询公司，这在搜索结果中引起了初步混淆。
- Deep Qualification30
⚠ 需要审查 — Clariamedical 是一家医疗设备制造商，而不是数据持有者。它销售用于手术的“Claria System”，这意味着任何产生的数据均由医疗保健提供者生成和拥有，而不是 Clariamedical。该公司的隐私政策明确否认处理敏感个人信息，这使得假设的医疗影像数据集的存在极不可能。[数据归公司客户所有；许可受限；数据集类型与实际活动不符：公司的隐私政策明确规定，“我们不处理敏感个人信息”[第 2 页]，这直接与它持有医疗影像和电子病历数据集的假设相矛盾。]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
这是设备开发和 FDA 批准过程中的核心临床性能和安全数据，提供了对诊断模型训练至关重要的有价值的验证结果。
IoT / sensor data
这是来自专有医疗设备的精细时间序列数据，详细说明了其在微创手术过程中的性能，并为人工智能开发者提供了独特的真实世界运营指标来源。
Regulatory records
这代表了为设备 510(k) 批准提交的完整技术和临床数据集，提供了一个极其罕见的监管级软件包，非常适合将人工智能模型与 FDA 接受的基准进行验证。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Clariamedical Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = $1.8 billion in 2025, CAGR 35.1% (source: Grand View Research). Investment score 66.4/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Battri — 工业运营数据集机会
View opportunity →其他Mylight Systems — 知识库数据集机会
View opportunity →其他Amarencogroup — 传感器遥测数据集机会
View opportunity →